#USA #CTXR #Cranford #Citius Pharmaceuticals #LYMPHIR

Citius Pharmaceuticals Completes $5 Million Offering

Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a biopharmaceutical company dedicated to the advancement of innovative critical care products, has recently announced the completion of a registered direct offering amounting to $5 million. This offering, priced at $0.985 per share, aligns with Nasdaq's market regulations and includes the sale of approximately 5,076,143 shares of common stock, along with pre-funded warrants. The deal was arranged to facilitate critical advancements in the treatment landscape, especially concerning their product LYMPHIR™.

Overview of the Offering

The offering was part of a larger strategic push by Citius Pharma to leverage existing market conditions under the regulatory framework established by the Nasdaq. Alongside the direct sale, a private placement was conducted where unregistered warrants were issued, allowing investors to purchase additional shares at an exercise price of $0.86 per share, effective upon issuance. This dual structure aims to enhance investor interest while providing necessary capital for the company's strategic initiatives.

H.C. Wainwright & Co. served as the exclusive placement agent for this financial maneuver, which garnered significant attention from market analysts and investors alike. The gross funds generated from this offering will primarily support the commercial launch of LYMPHIR, the company’s latest critical care innovation aimed at treating patients with specific types of cutaneous T-cell lymphoma (CTCL).

Utilization of Funds

The proceeds from this offering are expected to be utilized for various corporate tactics, including the following:

• - Launch Support for LYMPHIR: Funds will aid in milestone payments and regulatory transitions necessary for the product's market entry.
• - Development Initiatives: Investments will be funneled into ongoing projects for other candidates within Citius Pharmacy’s pipeline, showcasing the company’s commitment to holistic growth and patient care.
• - General Corporate Purposes: The financial influx is also set to bolster general operational needs, ensuring stable growth and cash flow management for future ventures.

LYMPHIR and Future Aspirations

LYMPHIR, a targeted immunotherapy developed by Citius Pharmaceuticals, was launched in December 2025, aimed at adults diagnosed with relapsed or refractory Stage I-III CTCL. The product signifies a significant breakthrough, offering targeted treatment for patients who have undergone prior systemic therapies but still face treatment resistance.

The firm is optimistic about LYMPHIR's potential to improve quality of life for patients and remains actively engaged with the FDA to ensure compliance and facilitate further research. The company’s future prospects also include expanding partnerships and enhancing international access to therapeutics, which is central to its strategic roadmap.

Financial Landscape and Market Positioning

Citius Pharmaceuticals currently retains approximately 71% control of Citius Oncology, which underlines its entrenched position in the biopharma landscape. Future plans will need to navigate market uncertainties while also addressing the pressing need for additional funding sources in light of continuous development costs. The ongoing Phase 3 trial for Mino-Lok, along with a Phase 2b trial for Halo-Lido, demonstrates the innovative pipeline that Citius Pharma is fostering, reinforcing its commitment to advancing patient care.

Conclusion

The successful closure of this $5 million offering positions Citius Pharmaceuticals favorably within the bustling biopharmaceutical sector. As the company transitions from developmental phases to market-ready products, stakeholders remain hopeful about the implications for both corporate growth and patient care. Citius’ continuous focus on strategic development coupled with effective fundraising will likely bolster its presence in a competitive therapeutic landscape. Notably, as Citius Pharma navigates federal regulations, the emphasis on transparency and compliance remains crucial.

For further inquiries or to engage with ongoing investor relations, stakeholders can reach out through the official Citius Pharmaceuticals contact points. As the company embarks on this critical juncture, the biopharma community will be closely monitoring their advancements in technologies that can reshape treatment for chronic conditions.